Current Report Filing (8-k)
December 09 2021 - 10:47AM
Edgar (US Regulatory)
0001053369 false 0001053369 2021-12-09
2021-12-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED
STATES
SECURITIES AND
EXCHANGE COMMISSION
WASHINGTON, D.C.
20549
FORM
8-K
CURRENT
REPORT
PURSUANT TO
SECTION 13 OR 15(D)
OF THE
SECURITIES EXCHANGE ACT OF 1934
December 9, 2021
Date of
Report (Date of earliest event reported)
ELITE PHARMACEUTICALS,
INC.
(Exact name
of registrant as specified in its charter)
|
Nevada |
|
001-15697 |
|
22-3542636 |
|
(State or
other jurisdiction |
|
(Commission |
|
(IRS
Employer |
|
of
incorporation) |
|
File
Number) |
|
Identification
No.) |
165 Ludlow Avenue,
Northvale,
New Jersey
07647
(Address of
principal executive offices)
(201)
750-2646
(Registrant’s telephone
number, including area code)
(Former name
or former address, if changed since last report.)
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425) |
|
|
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
|
|
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
|
|
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
Indicate by
check mark whether the registrant is an emerging growth company as
defined in as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
|
Title of
each class |
|
Trading
Symbol(s) |
|
Name of
each exchange on which registered |
|
Common Stock, par
value $0.001 per share |
|
ELTP |
|
OTCQB |
Item 1.01
Entry Into A Material Definitive Agreement
On December
6, 2021, Elite Pharmaceuticals Inc. (“Elite”) signed a License and
Distribution Agreement with Dexcel Ltd. (Or Akiva, Israel) to be
the exclusive distributor of Elite’s generic version of
Adderall® for
Israel.
Elite’s
generic version of Adderall® is an immediate-release mixed salt of
a single entity Amphetamine product (Dextroamphetamine Saccharate,
Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine
Sulfate). Adderall® is a central
nervous system (CNS) stimulant, indicated for the treatment of
Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy.
Dexcel will market the 10 mg, 20 mg, and 30 mg tablets.
Elite will
manufacture and package the generic product under Dexel’s label.
Dexcel will provide sales, marketing, and distribution, at its own
expense. Dexel will pay an agreed upon transfer price for the
product and will share any profits when the net selling price
exceeds a floor price. Elite’s generic Adderall® product is
jointly owned by Elite and Mikah Pharma LLC . The License
Agreement term is three years and may be extended for additional
1-year periods should specific terms be met.
Item 9.01
Financial Statements and Exhibits.
(d)
Exhibits.
|
Exhibit
No. |
|
Description |
| 104 |
|
Cover Page Interactive
Data File (embedded within the Inline XBRL document). |
SIGNATURE
Pursuant to
the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
| Dated: December 9,
2021 |
ELITE
PHARMACEUTICALS, INC. |
| |
|
|
|
By: |
/s/
Nasrat
Hakim |
| |
|
Nasrat Hakim, President
and CEO |
Elite Pharmaceuticals (QB) (USOTC:ELTP)
Historical Stock Chart
From Apr 2022 to May 2022
Elite Pharmaceuticals (QB) (USOTC:ELTP)
Historical Stock Chart
From May 2021 to May 2022
